Nature Reviews Drug Discovery

Vaccines for cancer prevention: exploring opportunities and navigating challenges

Michele Graciotti, Lana E. Kandalaft Feb 01, 2025 pp. 134-150 10.1038/s41573-024-01081-5

Antiviral target compound profile for pandemic preparedness

James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar et al. Feb 01, 2025 pp. 151-152 10.1038/s41573-024-01102-3

Targeting lysine acetylation readers and writers

Ming-Ming Zhou, Philip A. Cole Feb 01, 2025 pp. 112-133 10.1038/s41573-024-01080-6

2024 FDA approvals exceed average number but have lower sales projections

Mathias Baedeker, Michael S. Ringel, Clemens C. Möller Feb 01, 2025 pp. 85-85 10.1038/d41573-025-00014-0

Biopharma dealmaking in 2024

Patricia Giglio, Amanda Micklus Feb 01, 2025 pp. 86-87 10.1038/d41573-025-00013-1

Outlook for medicines development and use in 2025

Sarah Rickwood, Helena Bayley, Stefan Lutzmayer et al. Feb 01, 2025 pp. 73-74 10.1038/d41573-025-00012-2

DLL3 draws two antibody–drug conjugate deals

Asher Mullard Feb 01, 2025 pp. 84-84 10.1038/d41573-025-00011-3

Targeting inherited mutations to prevent metastasis

M. Teresa Villanueva Feb 01, 2025 pp. 90-90 10.1038/d41573-025-00009-x

FDA approves next-generation triple therapy for cystic fibrosis

Asher Mullard Feb 01, 2025 pp. 83-83 10.1038/d41573-025-00008-y

Cough suppressant reverses lung scarring

Sarah Crunkhorn Feb 01, 2025 pp. 91-91 10.1038/d41573-025-00006-0

Sodium channel blocker reduces skin inflammation

Sarah Crunkhorn Feb 01, 2025 pp. 91-91 10.1038/d41573-025-00005-1

Human brain organoids identify glioma inhibitors

Sarah Crunkhorn Feb 01, 2025 pp. 91-91 10.1038/d41573-025-00007-z

DNA-PKcs inhibitor causes genomic alterations

Sarah Crunkhorn Feb 01, 2025 pp. 91-91 10.1038/d41573-025-00004-2

Engineered T cells traverse new terrain

Katie Kingwell Feb 01, 2025 pp. 88-88 10.1038/d41573-025-00002-4

Lipid nanoparticle ferries therapeutic mRNA to the placenta

Alex Eccleston Feb 01, 2025 pp. 90-90 10.1038/d41573-025-00003-3

2024 FDA approvals

Asher Mullard Feb 01, 2025 pp. 75-82 10.1038/d41573-025-00001-5

Pairing up with GLP-1 to combat obesity

Sarah Crunkhorn Feb 01, 2025 pp. 89-89 10.1038/d41573-024-00205-1

FDA approves first HER2 × HER3 bispecific antibody

Asher Mullard Feb 01, 2025 pp. 83-83 10.1038/d41573-024-00206-0

Harnessing the biology of regulatory T cells to treat disease

Christine M. Wardell, Dominic A. Boardman, Megan K. Levings Feb 01, 2025 pp. 93-111 10.1038/s41573-024-01089-x